Cipla Limited has announced the superannuation of Dr Raju Mistry, Global Chief People Officer and Senior Management Personnel, effective December 31, 2025. The announcement was made through a regulatory filing under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Key Details of the Announcement

The pharmaceutical company submitted the disclosure on December 30, 2025, to multiple stock exchanges where its shares are listed. The filing confirms that Dr Mistry will retire from his position as Global Chief People Officer on the last day of 2025.

Regulatory Compliance

The disclosure was made pursuant to Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024. This regulation requires listed companies to inform stock exchanges about material events and information that could impact investor decisions.

Stock Exchange Notifications

Cipla submitted the announcement to three exchanges where its securities are traded:

• BSE Limited: Scrip Code 500087
• National Stock Exchange of India Limited: Scrip Code CIPLA EQ
• Societe de la Bourse de Luxembourg: International listing

The company stated that it will announce Dr Mistry's successor in due course, indicating that the transition planning process is underway. The filing was signed by Rajendra Chopra, Company Secretary, and prepared by Pavankumar Yadav.

About the Position

As Global Chief People Officer, Dr Mistry holds a senior management position responsible for human resources strategy and operations across Cipla's global operations. His superannuation marks the end of his tenure in this key leadership role at the pharmaceutical company.

Pfizer Limited has entered into an exclusive 5-year marketing and distribution agreement with Cipla Limited for four pharmaceutical brands in the Indian market. The partnership, disclosed through regulatory filing under Regulation 30 of SEBI listing requirements, grants Cipla sole rights to market and distribute key Pfizer brands across India.

Exclusive Partnership Details

Under the agreement, Cipla now has exclusive rights to market, distribute and sell four specific Pfizer brands. The partnership covers established therapeutic products across multiple categories, with Pfizer continuing to manufacture, source and supply these medicines to Cipla for the Indian market.

Brand Portfolio Coverage

The agreement encompasses four key pharmaceutical brands spanning different therapeutic areas. These products represent established market presence in their respective categories, providing Cipla with enhanced portfolio diversification.

Workforce Impact and Financial Implications

The partnership will result in certain reduction in Pfizer Limited's field force as part of the transition to Cipla's distribution network. Pfizer has committed to supporting impacted colleagues for their career transition during this organizational change.

Strategic Market Implications

Meenakshi Nevatia, Country President of Pfizer India, emphasized that expanding medicine reach for patients remains paramount, highlighting the partnership's potential to serve millions of patients across India effectively. The collaboration combines Pfizer's legacy of quality and innovation with Cipla's extensive distribution network.

Achin Gupta, Global Chief Operating Officer at Cipla, noted that meaningful partnerships help make strong brands even stronger. The association aligns with Cipla's continued focus on building formidable presence across key therapy areas while enhancing access to high-quality treatments guided by their purpose of "Caring for Life."

Commercial Framework

The agreement involves no upfront consideration between the parties, with other commercial terms agreed upon privately. This marks the first partnership between Pfizer and Cipla in India, combining Pfizer's well-established portfolio with Cipla's deep market penetration capabilities across the country's pharmaceutical distribution network.